Attachment 4 - Page 1 
a 
ABMT 
P 
BL 
CEA 
CF 
CML 
CMV 
CT 
CTL 
DNA 
EPA 
FACC 
FDA 
GAG 
G-CSF 
GCV 
GVH 
HLA 
HSV-TK 
IBC 
IL 
IRAP 
IRB 
IRES 
kg 
MDR-1 
mg 
MHC 
ml 
mRNA 
NCI 
neo^ 
NIH 
ng 
NIH Guidelines 
NSCLC 
OPRR 
ORDA 
PCR 
PFU 
PI 
ACRONYMS 
alpha 
autologous bone marrow transplantation 
beta 
biosafety level 
carcinoembryonic antigen 
cystic fibrosis 
chronic myelogenous leukemia 
cytomegalovirus 
computed tomography 
cytotoxic T lymphocyte 
deoxyribonucleic acid 
Environmental Protection Agency 
Fanconi anemia complementation group C 
Food and Drug Administration 
glycosaminoglycan 
granulocyte colony stimulating factor 
ganciclovir 
graft-versus-host 
human leukocyte antigen 
herpes simplex virus thymidine kinase 
Institutional Biosafety Committee 
interleukin 
interleukin-1 receptor antagonist protein 
Institutional Review Board 
internal ribosome entry sites 
kilogram 
multidrug resistance type-1 
microgram 
milligram 
major histocompatibility complex 
milliliter 
messenger ribonucleic acid 
National Cancer Institute 
neomycin resistance 
National Institutes of Health 
nanogram 
NIH Guidelines for Research Involving Recombinant DNA Molecules 
non-small cell lung cancer 
Office for Protection from Research Risks 
Office of Recombinant DNA Activities 
polymerase chain reaction 
plaque forming units 
principal investigator 
(384) 
Recombinant DNA Research, Volume 19 
